Search

Perfluorohexyloctane

[A259746, A259751] Perfluorohexyloctane has been used in the field of ophthalmology as a vitreous substitute. … [A259741] It was approved by the FDA on May 18, 2023 for the treatment of dry eye disease.[L46536]

Chromic nitrate

Bedaquiline

[A261856,A261861] It is the first drug that was approved in the last 40 years by the FDA for TB unresponsive to current treatments on the market. … [A261861] Bedaquiline was approved by the FDA on December 28, 2012, to treat pulmonary MDR-TB, following favorable results in multiple pre-clinical and clinical studies.

Chlordiazepoxide

It has also been used in the symptomatic treatment of alcohol withdrawal.

Estazolam

It has been shown in some cases to be more potent than diazepam or nitrazepam.

Etrasimod

[L48501] The European Commission also approved the marketing of etrasimod on February 19, 2024.[L50998] … [A261831] Etrasimod was approved on October 13, 2023, by the FDA under the brand name VELSIPITY for the treatment of adults with moderately to severely active ulcerative colitis.

Diatrizoate

As diatrizoate meglumine and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography.

Betamethasone phosphate

[L11994] Betamethasone sodium phosphate was granted FDA approval on 3 March 1965.[L11994]

Rilpivirine

[A31331] Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011. … [L1030] On November 21, 2017, Rilpivirine, in combination with [dolutegravir], was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named

Garadacimab

[L53283] It was developed by CSL Behring for use as a prophylactic agent in patients with hereditary angioedema (HAE), a rare autosomal dominant disorder that results in acute episodes of angioedema. … [A273993] In June 2025, garadacimab was approved by the US FDA for the prophylaxis of HAE episodes in patients ≥12 years of age.